Company Insights

HSCS customer relationships

Explore interactive graphBrowse insights index
HSCS customer relationship map

Heart Test Laboratories (HSCS): Customer relationships and what they signal to investors

Heart Test Laboratories (HSCS) develops the MyoVista wav ECG device and the MyoVista Insights Cloud Platform and monetizes via capital sales of hardware, recurring consumables (proprietary electrodes), and recurring software/licensing fees for AI-ECG algorithms delivered on-device or via the cloud. Revenue is therefore a mix of spot hardware sales, razor‑razorblade consumable revenue, and expected subscription or usage‑based software fees tied to algorithm access and cloud delivery. For a tactical read on commercial traction and counterparty mix, see more at https://nullexposure.com/.

Market-facing customer signals: the recorded relationship entries

Below are the four relationship records in the source results. Each entry below is translated into plain English with source attribution.

Cibolo Rural Health Networks — (FY2022, CNBC/TipRanks)

HeartSciences’ MyoVista Insights was selected by Cibolo Rural Health Networks, indicating an early commercial adoption of the company’s cloud application by a rural provider network focused on frontline screening. Source: TipRanks coverage cited on the CNBC HSCS quote page (item dated January 29, 2026; referenced on CNBC HSCS profile).

Cibolo Rural Health Networks — (FY2025, CNBC/TipRanks)

A second record tied to the HSCSW quote page reiterates the MyoVista Insights selection by Cibolo Rural Health Networks, reflecting continued visibility of the adoption in later filings or market reports. Source: TipRanks coverage cited on the CNBC HSCSW quote page (January 29, 2026; referenced on CNBC HSCSW profile).

UWE — (FY2022, CNBC/TipRanks)

HeartSciences announced that UWE adopted MyoVista Insights and the MyoVista wavECG device, signalling that the company is winning customers for both software and hardware in parallel. Source: TipRanks coverage cited on the CNBC HSCS quote page (reported February 5, 2026; referenced on CNBC HSCS profile).

UWE — (FY2025, CNBC/TipRanks)

A second record under HSCSW repeats the UWE adoption announcement, confirming the market notice for the combined device + cloud offering across reporting periods. Source: TipRanks coverage cited on the CNBC HSCSW quote page (February 5, 2026; referenced on CNBC HSCSW profile).

What these customer ties collectively reveal about HSCS’s operating model

The relationship entries are early‑adopter wins for both the MyoVista Insights cloud application and the MyoVista wavECG hardware. Combine that factual record with the company’s public disclosures and you get a consistent commercial profile:

  • Contracting posture: HeartSciences operates with a mix of transactional hardware sales and longer‑running frameworks for capital and equity (e.g., equity line / ATM facility). The company explicitly uses spot hardware sales plus recurring consumables and is building subscription/usage-based pricing for cloud algorithms. Evidence in filings documents an Equity Distribution Agreement and a Lincoln Park purchase agreement establishing multi‑month financing frameworks (36 months) rather than one‑off capital events.
  • Revenue mix and criticality: The business model is hardware-led with recurring software and consumables (the classic razor/razorblade), which increases lifetime value per installed unit but makes initial device adoption critical to the revenue ramp.
  • Customer concentration and counterparty types: Filings emphasize sales targets that include large health systems, primary care/physicians, and government payors (Medicare/Medicaid). That positions HSCS at the intersection of provider buying committees and third‑party reimbursement processes—sales cycles will be long and reimbursement is a gating factor.
  • Geographic go‑to‑market: The company targets the U.S. and Europe first, while positioning the product for global distribution; regulatory clearance (FDA and EU MDR/CE certification) is a hard dependency for scale.
  • Stage and maturity: Public statements mark the company as development-stage with limited revenue to date but with two named early adopter customers and active equity‑funding mechanisms. Filings indicate both active customers and many prospects/pilot plans—this is a classic early commercial ramp rather than a mature installed base.
  • Commercial roles: HSCS is simultaneously seller (of devices and algorithms), platform service provider (cloud hosting and algorithm delivery), and manufacturer for the hardware; it also uses distributors/resellers and selling agencies for capital raises and market access.

These signals combine into a clear operating shape: capital‑intensive device launch followed by recurring consumables and subscription income, but dependent on regulatory clearance, physician adoption, and third‑party reimbursement.

Mid‑report action: if you want a compact, investor-ready summary and ongoing tracking of customer wins and filings, visit https://nullexposure.com/ for the latest updates.

How to read the commercial risk / reward from these relationships

  • Upside: Early adoptions by networks like Cibolo and customers such as UWE validate a go‑to‑market that bundles device + cloud, increasing the odds of cross‑sell (hardware → consumables → software). If HSCS secures Medicare/insurer reimbursement for algorithms, the economics are attractive because software and consumables scale faster than one‑time hardware sales.
  • Risk factors to price in: Regulatory clearance (FDA) and EU certification are nonnegotiable gating items; filings make this explicit. Reimbursement uncertainty and long buying cycles at health systems mean revenue realization will be lumpy and tied to pilot performance and coding/AMA approvals. Inventory obsolescence, product liability, and physician acceptance are material risks noted in the company filings.
  • Financial posture / funding risk: HSCS is using equity distribution facilities and structured purchase agreements for liquidity (up to $15.0 million facilities cited in filings), which dilutes existing shareholders but provides runway for commercialization and regulatory work. Expect follow‑on capital events as a likely necessity until subscription traction is demonstrable.
  • Commercial durability: The razor‑razorblade consumables strategy and cloud subscription model create potential for sticky, recurring revenues once adoption and reimbursement are secured; however, this payoff depends on scaling clinician adoption and compliance with privacy/security standards for cloud‑hosted patient data.

Bottom line and next actions for investors and operators

  • Key takeaway: HSCS is a hardware‑led medtech with early adopter customers for both device and cloud; the commercial model is intentionally a hybrid of one‑time device revenue plus recurring consumables and subscription software fees. Regulatory clearance and reimbursement are the principal value inflection points.
  • For operators: Focus commercial efforts on clearing regulatory gates, securing reimbursement codes, and documenting cost‑effectiveness in early pilots to shorten procurement cycles with health systems.
  • For investors: Monitor pilot outcomes, reimbursement milestones, and cash runway; early wins like Cibolo and UWE prove product interest but do not yet prove scale.

For ongoing monitoring of customer wins, filings, and how those translate to commercial revenue, visit https://nullexposure.com/. To request a tailored briefing or a deeper coverage pack on HSCS customer relationships, see our homepage at https://nullexposure.com/ and contact our research desk.